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Renal cellCyst growth and expansion in autosomal dominant polycystic kidney disease (ADPKD) has been attributed to
numerous factors, including ATP, cAMP and adenosine signalling. Although the role of ATP and cAMP has
been widely investigated in PKD1-deﬁcient cells, no information is currently available on adenosine-
mediated signalling. Here we investigate for the ﬁrst time the impact of abnormalities of polycystin-1 (PC1)
on the expression and functional activity of adenosine receptors, members of the G-protein-coupled receptor
superfamily. Pharmacological, molecular and biochemical ﬁndings show that a siRNA-dependent PC1-
depletion in HEK293 cells and a PKD1-nonsense mutation in cyst-derived cell lines result in increased
expression of the A3 adenosine receptor via an NFkB-dependent mechanism. Interestingly, A3 adenosine
receptor levels result higher in ADPKD than in normal renal tissues. Furthermore, the stimulation of this
receptor subtype with the selective agonist Cl-IB-MECA causes a reduction in both cytosolic cAMP and cell
proliferation in both PC1-deﬁcient HEK293 cells and cystic cells. This reduction is associated with increased
expression of p21waf and reduced activation not only of ERK1/2, but also of S6 kinase, the main target of
mTOR signalling. In the light of these ﬁndings, the ability of Cl-IB-MECA to reduce disease progression in
ADPKD should be further investigated. Moreover, our results suggest that NFkB, which is markedly activated
in PC1-deﬁcient and cystic cells, plays an important role in modulating A3AR expression in cystic cells.© 2009 Elsevier B.V. All rights reserved.1. Introduction
Autosomal dominant polycystic kidney disease (ADPKD) is the
most common hereditary renal disorder (1 in 500–1000 people), and
accounts for approximately 10% of all cases of ESRD [1]. It is
characterized by progressive formation and enlargement of multiple
ﬂuid-ﬁlled cysts in both kidneys, and leads to renal failure in
approximately 50% of patients in their 5th or 6th decade of life [1,2].
Genetically, ADPKD is caused by loss-of-function mutations in the
PKD1 and PKD2 genes, which encode polycystin-1 (PC1) and
polycystin-2 (PC2) [3,4]. PC1 is a large integral membrane proteinand Molecular Biology, Via L.
fax: +39 532 202723.
ll rights reserved.required for activation of cation permeable currents [5,6] and
regulation of cell cycle [7], G-protein signalling [8,9] and perhaps
adenylyl cyclase (AC) activity [10], and mutations in the PKD1 gene
account for the vast majority of ADPKD cases (∼85%), which are those
associated with a more severe clinical presentation [1,2].
AC activity in PKD cells is highly relevant, as intrarenal production
of 3′:5′-cyclic monophosphate (cAMP) plays a major role in the
pathogenesis of ADPKD by stimulating transepithelial secretion,
accumulation of cystic ﬂuid and cell proliferation [10]. In particular,
the disruption of PC1 could result in enhancement of cAMP levels and
induction of cystic cell proliferation via activation of the B-Raf/MEK/
ERK pathway [11,12]. Consistently, administration of antagonists of
receptors for AC agonists markedly inhibits disease development in
ADPKD animal models [13,14].
It has also been found that cAMP, when it reaches either
the apical or basolateral membranes of proximal tubular cells, is
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primordial signalling molecule, which, through the activation of
speciﬁc surface G-protein-coupled receptors (GPCR) [16], modulates
several processes, among which proliferation, survival and apoptosis
[17], in numerous cell types, including kidney cells [18,19]. Although
adenosine signalling has already been proposed to be detrimental to
ADPKD cyst growth and expansion [20], little is known about the
role of adenosine receptors (AR) in the regulation of cAMP
production, cAMP-related pathways or cell proliferation in ADPKD
cystic cells.
We report here that PC1-depleted HEK293 cells and PKD1-
mutated cystic cells express increased levels of AR type 3 (A3AR),
which is associated with, if not sustained by, increased activation of
the transcription factor NFkB. Interestingly, the stimulation of A3AR
with the speciﬁc agonist Cl-IB-MECA causes a reduction in cell
proliferation and in ERK1/2 and S6 kinase activities in cystic cells.
These ﬁndings pave the way to future investigations into the role of
Cl-IB-MECA in preventing or slowing renal cyst growth in ADPKD
animal models.
2. Materials and methods
2.1. Reagents
D-MEM/F12 and MEM media, Bovine Serum Albumin (BSA), N6-
(3-iodo-benzyl)2-iodo-benzyl)-2-chloroadenosine-5′-N-methyluro-
namide (Cl-IB-MECA), 1,3-dipropyl-8-cyclopentylxanthine (DPCPX),
N6-cyclohexyladenosine (CHA), 5′-N-ethylcarboxamidoadenosine
(NECA), 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone (RO
201712) and forskolin were purchased from Sigma (Milano, Italy).
FBS, Glutamine and antibiotics were obtained from Eurobio (Celbio,
Italy), and protease inhibitors from Roche Diagnostics (Monza, Italy).
5-amino-7-(phenylethyl)-2-(2-furyl)-pyrazolo[4,3-e]-1,2,4,triazolo
[1,5-c]pyrimidine (SCH 58261) was purchased from Tocris, Ltd, UK.
5-n-(4-methoxyphenyl-carbamoyl) amino-8-propyl-2-(2-furyl)pyra-
zolo[4,3-e]-1,2,4-triazolo [1,5-c] pyrimidine (MRE 3008F20) and N-
benzo[1,3] dioxol-5-yl-2-[5-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahy-
dro-1H-purin-8-yl)-1-methyl-1H-pyrazol-3-yloxy]-acetamide (MRE
2029F20) were synthesized by Prof. P.G. Baraldi, Ferrara University,
Italy. The radioligand [3H]-1,3-dipropyl-8-cyclopentyl-xanthine ([3H]-
DPCPX), speciﬁc activity 120 Ci/mmol, was obtained fromNEN-Perkin
Elmer Life and Analytical Sciences, USA. [3H]-4-(2-[7-amino-2-(2-
furyl)[1,2,4] triazolo[2,3-a] [1,3,5] triazin-5-yl-amino]ethyl ([3H]-ZM
241385), speciﬁc activity 27.4 Ci/mmol, was obtained from American
Radiolabeled Chemicals Inc., Saint Louis, MO, USA. [3H]-N-benzo [1,3
[dioxol-5-yl-2-[5-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-
purin-8-yl)-1-methyl-1H-pyrazol-3-yl-oxy]-acetamide ([3H]-MRE
2029 F20), speciﬁc activity 123 Ci/mmol, and [3H]-5N-(4-methox-
yphenylcarbamoyl) amino-8-propyl-2-(2-furyl) pyrazolo[4,3-e]-
1,2,4-triazolo [1,5-c]pyrimidine ([3H]-MRE 3008F20), speciﬁc activity
67 Ci/mmol, were obtained from Amersham International Chemical
Laboratories, Buckinghamshire, UK. Rabbit polyclonal anti-actin, anti-
β-tubulin, anti-PC1, anti-A3AR and anti-SV40 Tag antibodies were
obtained from Santa Cruz (DBA Italia Srl, Segrate, Italy), while rabbit
polyclonal anti-S6 kinase, anti-pS6 kinase, Erk1/2 and pErk1/2
antibodies were obtained from Cell Signaling Technology (Celbio
SRL, Italy). Enhanced chemiluminescent substrates for Western
blotting (SuperSignalDura or SuperSignalFemto) and HRP conjugated
goat anti-rabbit and anti-mouse antibodies were purchased from
Pierce (Celbio Srl, Italy).
2.2. Cell lines and tissues
HEK293pSsiPKD1 and HEK293pSuper cells, which were previously
obtained by stable transfection of HEK293 cells with pSsiPKD1
vectors expressing PKD1 siRNA and the pSUPER empty vector,respectively [21], were cultured in MEM 10% FBS. HEK293pSsiPKD1
cells were repeatedly monitored for the extent of PC1 depletion, and
two clones (a1 and b3) maintaining an approximate 85% reduction in
PC1 were used in the current studies (see the PC1 percent values in
inset of Figs. 1A and 4B). SV40-transformed human cell lines, one
derived from normal (4/5) and two from cystic kidney cell lines [22]
(all expressing comparable levels of T antigen, data not shown) were
grown in Dulbecco's modiﬁed Eagle's medium/F12, 10% FBS. Cystic
cells carry the Q2556X PKD1 mutation: one is heterozygous (9.7),
while the other is hemizygous (9.12), for deletion of the normal allele
[22]. Tissue samples of adult kidneys with normal histology were
obtained from renal tumor nephrectomy patients (a male 54 yr old
and a female 58 yr old). ADPKD kidneys were obtained from ADPKD
patients (three males 53, 55 and 58 yr old and a female 55 yr old)
who had the typical clinical manifestations and reached endstage
renal disease, during transplant nephrectomy. The diagnosis was
veriﬁed by anatomic examination. Explicit genotypic data were not
available. The study protocol was in line with the ethical guidelines of
the 1975 Declaration of Helsinki.
2.3. Saturation binding experiments to purinergic receptors
Cells were resuspended in ice-cold hypotonic buffer (5 mM Tris
HCl, 2 mM EDTA, pH 7.4), homogenized and centrifuged for 30 min
at 100,000 g. The membrane pellet was resuspended in the buffer
solution used in binding experiments, incubated with 2 IU/ml of
adenosine deaminase for 30 min at 37 °C and centrifuged for 30 min
at 100,000 g. Finally, the membrane suspension (40–60 μg protein/
assay) was used in experiments of saturation binding to A1, A2A, A2B
and A3 adenosine receptors that were performed by using [3H]-
DPCPX, [3H]-ZM 241385, [3H]-MRE 2029 F20 and [3H]-MRE
3008F20, respectively, according to previously described methods
[23].
2.4. Real-time PCR
Total cytoplasmic RNA was extracted by the guanidinium
thiocyanate phenol method, reverted with random primers and A3
mRNA quantitative real-time RT-PCR assay was carried out using a
gene-speciﬁc double ﬂuorescently labeled TaqMan MGB probe
(minor groove binder) in an ABI Prism 7700 Sequence Detection
System (Applied Biosystems, Warrington Cheshire, UK) as previously
reported [24]. The following primer and probe sequences were used
for real-time RT-PCR: A3 forward primer, 5′-ATG CCT TTG GCC ATT
GTT G-3′; A3 reverse primer, 5′-ACA ATC CAC TTC TAC AGC TGC CT-3′;
A3 MGB probe, 5′-FAM-TCA GCC TGG GCA TC-TAMRA-3′ (Applied
Biosystems, Monza, Italy). The endogenous control human β-actin kit
was used for real-time RT-PCR of the reference gene, and the probe
was ﬂuorescent-labeled with VIC (Applied Biosystems). A3AR RNA
quantiﬁcation was obtained by the ΔCT method. Final results,
expressed as Nfold content in A3AR gene expression relative to the
ACTIN gene, were determined as follows: N(target)=2−ΔΔCT, as
previously described [25].
2.5. Measurement of cyclic AMP levels
Cells (1–2×106) were suspended in 0.5 ml of Krebs Ringer
phosphate buffer, containing 1.0 IU adenosine deaminase ml−1, and
0.5 mM 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone (Ro 20–
1724) as phosphodiesterase inhibitor, then pre-incubated for 10 min
at 37 °C. The cells were also incubated with forskolin (1 μM) and/or
Ro 20–1724 (0.5 mM) to evaluate the adenylyl cyclase activity.
Subsequently the effect of typical adenosine agonists was studied by
using CHA, NECA and Cl-IB-MECA at different concentrations
(1 nM–1 μM) for a further 5 min. In addition, the effects of typical
adenosine antagonists such as DPCPX (A1), SCH 58261 (A2A), MRE
Fig. 1. Expression of AR subtypes in human kidney cell lines. Bars show receptor density (Bmax, fmol/mg protein) of adenosine receptors (A1, A2A, A2B and A3) in PC1-depleted
HEK293pSsiPKD1 and control HEK293pSuper cells (see inset) (A), and in PKD1-mutated cystic 9.7, 9.12 and wild-type tubular 4/5 cells (B). Immunoblot analysis shown in the inset was
performed as previously reported on p100 membrane fractions (100 μg/lane) [21]. Bars show mean±SE of at least three independent experiments in duplicate (⁎⁎, pb0.01 vs.
control cells). Data obtained from HEK293pSsiPKD1 a and b clones have been combined. Saturation curves of [3H]-MRE 3008F20 binding to A3AR in 4/5, 9.7 and 9.12 cell membranes,
and Scatchard plot of the same data (C). Overall binding parameters including afﬁnity (KD, nM) are shown in Table 1. (D) A3ARmRNA expression in 9.7 and 9.12 relative to those in 4/
5 cells. Levels of A3AR mRNAwere measured by real-time RT-PCR. Experiments were performed as described in Materials and methods. Bars show mean±SD of three independent
experiments in duplicate (⁎ and ⁎⁎, pb0.05 and 0.01 vs. control cells). (E and F) A3AR protein expression in kidney cell lines and tissues. A3AR levels were measured by immunoblot
analysis of total lysates of cultured cells (50 μg/lane) (E), and from membranes of kidney tissue samples (F). Fractions containing plasma membranes, P8 (25 μg/lane) and those
containing reticular membranes, P100 (50 μg/lane), were obtained from four ADPKD and two control kidneys, as reported in Materials and methods. Bars show mean±SD of three
independent experiments. A signiﬁcant ∼3 fold increase was observed in both PKD1-deﬁcient cells and ADPKD tissues (⁎⁎ and ⁎⁎⁎, pb0.01 and b0.001 vs. control cells). Data from
cystic and PC1-depleted cells, as those from P8 and P100 fractions, have been combined.
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was terminated by the addition of 6% trichloroacetic acid cold
solution (TCA). The TCA suspension was centrifuged at 2000 g for10 min at 4 °C and the supernatant was extracted four times with
water-saturated diethyl ether. The ﬁnal aqueous solution was tested
for cyclic AMP levels by a competition protein binding assay [26].
Table 1
Afﬁnity and density of adenosine receptors in PC1-deﬁcient kidney cell membranes.
A — HEK 293pSuper and HEK293pSsiPKD1 cell membranes
Cells [3H]-DPCPX
A1AR
[3H]-ZM 241385
A2AAR
[3H]-MRE2029F20
A2BAR
[3H]-MRE3008F20
A3AR
293pSuper
KD 2.78±0.20 2.40±0.15 1.71±0.18 3.46±0.07
Bmax 13±2 44±3 27±2 154±8
n=3 n=6 n=3 n=8
293pSsiPKD1
KD 2.63±0.22 2.55±0.22 1.87±0.23 3.51±0.18
Bmax 12±2 40±3 25±2 263±22⁎⁎
n=3 n=7 n=3 n=9
B — Tubular (4/5) and PKD1-mutated cystic (9.07 and 9.12) cell membranes
Cells [3H]-DPCPX
A1AR
[3H]-ZM 241385
A2AAR
[3H]-MRE2029F20
A2BAR
[3H]-MRE3008F20
A3AR
4/5
KD 5.45±0.21 2.28±0.12 2.75±0.13 4.04±0.12
Bmax 3633±233 503±23 287±24 783±44
n=3 n=3 n=3 n=3
9.7
KD 5.39±0.20 2.31±0.11 2.66±0.11 4.22±0.24
Bmax 3587±247 510±38 270±21 1150±58⁎⁎
n=3 n=3 n=3 n=3
9.12
KD 5.36±0.13 2.39±0.18 2.85±0.10 4.37±0.19
Bmax 3600±231 513±35 277±23 1383±60⁎⁎
n=3 n=3 n=3 n=3
Binding parameters such as afﬁnity (KD, nM) and density (Bmax, fmol/mg protein) in
HEK293pSsiPKD1 and control HEK293pSuper cells (A), and in PKD1-mutated 9.7, 9.12 cells
and in control 4/5 cells (B). n=number of experiments; ⁎⁎, pb0.01 relative to PC1-
deﬁcient vs. control cells.
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Cells were plated overnight in 24-well plates at density of
30,000 cells/ml in 10% FBS-supplemented medium. After plating,
cells were starved for 24 h in medium supplemented with 0.4% BSA,
and then cultured for 24 h and 72 h in medium containing 1% FBS,
alone or in combinationwith CL-IB-MECA (1, 10, 100 and 1000 nM), or
CL-IB-MECA and MRE 8000F20 (1 μM). MRE 8000F20 inhibitor was
added 30 min before treatment with the A3AR agonist CL-IB-MECA.
Cell proliferation was calculated by direct cell counting after trypan
blue staining, using a Burker chamber [27].
Cell cycle analysis was carried out by ﬂow cytometry of propidium
iodide-treated cells, using the FACSCalibur Becton Dickinson Immu-
nocytometry Systemaccording to theBectonDickinsonprocedure [27].
2.7. Caspase 3 assay
Caspase 3 activity was evaluated using EnzChek® caspase-3 Assay
Kit (Invitrogen). After treatment with 1% FBS alone or in combination
with 100 nM Cl-IB-MECA for 24 h, cells were harvested, lysed and
centrifuged according to the manufacturer's instructions. 50 μl
aliquots of supernatant were incubated with 50 μl of 2× substrate
working solution containing 5 mM Z-DEVD-R110. Fluorescence was
measured every min for 90 min at 520 nm by a ﬂuorimeter (VICTOR3
1420Multilabel Counter, PerkinElmer). Values were normalized to the
amount of protein samples by the Bradford method.
2.8. Western blotting
Cells were collected and lysed in a 1% Triton X-100 solution
containing a cocktail of protease inhibitors (Roche, Milan, Italy), and
processed for immunoblots as described [28]. For protein phosphor-
ylation analysis, cell lysates were supplemented with 10 mM sodium
pyrophosphate and 1 mM sodium vanadate. Total proteins were
subjected to10% SDS-polyacrylamide gel electrophoresis. Cell mem-
branes were prepared as previously reported [27]. Cells and tissues
were homogenized (Dounce) and centrifuged at 8000 g for 20 min,
and the pellet was solubilized (P8 fraction, containing plasma
membranes, debris and nuclei), while the supernatant was subse-
quently centrifuged at 100,000 g (45 min). The pellet obtained was
resuspended in single detergent lysis buffer [27] (P100 membrane
fraction). Aliquots of P8 (25 μg) and P100 (50 μg) fractions were
analysed on both 10% and 5% SDS-polyacrylamide gel. Different
amounts of proteins (100–20 μg, as indicated) were resolved on gels
depending on the detectability of probed protein. Blockedmembranes
were probed overnight at 4 °C with primary antibody, and incubated
with the secondary antibody in 5%milk in PBS-T. Finally, proteins were
visualized by using the SuperSignalFemto chemiluminescence system
(Pierce, Celbio, Milan, Italy). Band intensity was detected by X-ray ﬁlm
scanning and quantitative analysis by a Model GS-700 Imaging
Densitometer (BIO-RAD, Milan, Italy).
2.9. NFkB luciferase assay and NFkB ﬂuorescence analysis
After 24 h plating in a 6-well plastic plate, cells were transiently
transfectedwith 4 μg of pNFkB-TA-Luc plasmid DNA (Clontech, Celbio Srl,
Italy) by the Ca2+ phosphate method, and, 6 h post-transfection, were
washed and incubated for an additional 20 h in medium supplemented
with 1% FBS. After cell treatment with passive lysis buffer (Promega,
Madison, WI, USA), 25 μl of cell lysate was added to 50 μl of luciferase
substrate (Promega) and the sampleswere then analysed using a 20/20 n
luminometer (Turner Biosystems, Sunnyvale, CA, USA). Data were
expressed as relative ﬁreﬂy luciferase units (RLUS) normalized by the β-
galactosidase units, and as n-fold change with respect to control cells.
Fluorescenceanalysiswasperformedoncells transfectedwithNFkB-GFP
construct by using the Ca2+ phosphate procedure [25]. NFkB subcellularlocalization was analysed using a digital ﬂuorescence microscope, and
images were captured and recorded using a digital-imaging system [25].
2.10. Statistical analysis
Aweighted non-linear least-square curve-ﬁtting program Ligand was
used for computer analysis of saturation binding experiments. Analysis of
datawas performed using Student's t test (unpaired analysis). Differences
were considered signiﬁcant at a value of pb0.05. All data are reported as
mean±SEM or ±SD of independent experiments (n=3–8).
3. Results
3.1. A3AR expression is increased in PC1-deﬁcient cells
We initially investigated the expression of AR in PC1-depleted
HEK293 cells (HEK293pSsiPKD1) that were produced by knockdown of
PC1 through stable expression of PKD1 siRNA [21], and showed a
constant ∼85% reduction in PC1 levels (see PC1 percent values in inset
of Figs. 1A and 4B).
The presence of AR subtypes was examined in membranes by
evaluating antagonist radioligand binding to A1, A2A, A2B and A3
adenosine receptors. The mean values of receptor density (Bmax,
fmol/mg protein) and afﬁnity (KD, nM) in HEK293pSsiPKD1 and
HEK293pSuper control cells are shown Table 1A. Both cell types express
the four ARs and the highest density values were found for A3AR
(A3NA2ANA2BNA1). While afﬁnity values were similar between the
different cells (Table 1A), A3AR density resulted 1.7-fold higher in
HEK293pSsiPKD1 than in control cells (pb0.01) (Fig. 1A), indicating a
possible link between PC1-knockdown and A3AR increase.
To further investigate this link, similar experimentswere performed in
tubular cells (4/5) derived from a normal kidney, and in cystic cells (9.7
and 9.12) derived from a polycystic kidney carrying the PKD1-Q2556X
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HEK293 cells, tubular and cystic cells expressed the four ARs at markedly
higher levels (1 or 2 orders ofmagnitude), while afﬁnity values for A1, A2B
and A3AR were only slightly increased (Table 1B). Density values were
higher for A1AR (A1NA3NA2ANA2B). However, in PKD1-mutated hetero-
zygous 9.7 and hemizygous 9.12 cystic cells, A3AR densities were 1.47 and
1.76-fold higher than in tubular cells, as detailed by saturation curves and
the corresponding Scatchard plot shown in Fig. 1C. The increase in A3AR
density was thus associated with PC1 deﬁciency.
Consistently with increase in A3AR density, PKD1-mutated cystic
cells showed increased A3AR mRNA levels in comparisonwith tubular
cells (Fig. 1D) (1.6 and 2.53-fold increases in levels of RNA,
respectively, in 9.12 vs. 4/5 cells, pb0.05). This increasewas consistent
with that of A3AR protein levels detected by immunoblotting
experiments not only in cystic and HEK293pSsiPKD1 cultured cells
(Fig. 1E), but also in ADPKD kidney tissues (Fig. 1F).
These results show that PC1 depletion, either by PKD1 knockdown
or by itsmutation, is associatedwith a constant rise in A3ARexpression
accompanied by possible functional deﬁcits in PC1-deﬁcient cells.
3.2. A3AR activation causes different decreases in cAMP levels in tubular
and cystic cells
It is known that AR occupation is followed by alteration in cAMP
levels because A2A and A2B ARs stimulate AC activity whereas A1 and
A3 ARs inhibit it [16]. Therefore, in order to verify the functional
activity of the abovementioned A3AR increase, cAMP levels were
investigated in tubular and cystic cells. Basal cAMP levels, as well as
those induced by the presence of either phosphodiesterase inhibitor
(RO201712) or direct AC activator (forskolin), alone or in combination,
did not differ in 9.7 and 9.12 cystic cells from those in 4/5 tubular cells
(Fig. 2A). Moreover, cAMP levels in tubular and cystic cells in the
presence of RO201712 (Fig. 2B) were similarly increased by the
treatment with a speciﬁc A2AR agonist (NECA), and reduced by theFig. 2. Effect of adenosine receptor subtypes on cAMP levels in 4/5, 9.7 and 9.12 cell lines.
(white), 9.7 (light grey) and 9.12 cells (dark grey). Modulation of cAMP levels (B) by typic
58261 (1 μM) and the A2BAR antagonist MRE 2029F20 (100 nM); (C) by typical A1AR ligands
the agonist Cl-IB-MECA (100 nM), the antagonist MRE 3008F20 (1 μM), ⁎, pb0.05 of 9.7 an
Materials and methods. Bars represent the means±SD of four experiments.presence of either A2B or A2A AR antagonists (MRE2029F20 and
SCH58261, respectively). Furthermore, in tubular and cystic cells,
RO201712 and forskolin-associated cAMP levels were reduced, with-
out statistical signiﬁcance, by the presence of the speciﬁc A1AR agonist
CHA, but not by the speciﬁc A1AR antagonist DPCPX (Fig. 2C). In
contrast, in the presence of the speciﬁc A3AR agonist Cl-IB-MECA [29],
the inhibition of cAMP levels (which was reverted by the addition of
the speciﬁc A3AR antagonistMRE3008F20) [26] was smaller in tubular
than in cystic cells (1.4, 1.8 and 2.1-fold reductions in 4/5, 9.7 and 9.12
cells, respectively, pb0.05 in 9.7 and 9.12 vs. 4/5 cells) (Fig. 2D). Since
A3AR activation is associated with reduction in AC activity, these
results are consistent with the increased A3AR density observed in
cystic cells, and strongly support a functional role for A3AR increase in
cystic cells.
3.3. A3AR activation provokes different proliferation patterns in tubular
and cystic cells
On the basis of known cAMP inhibition by A3AR activation and
pathogenic roles of intracellular cAMP on PKD cyst growth [10–14],
cell proliferationwas investigated in cells stimulated with the speciﬁc
A3AR-agonist Cl-IB-MECA. After both 24 and 72 h incubations, 1%
FBS-induced cell proliferation was higher in cystic than in tubular
cells (Fig. 3A). 24 h treatment with Cl-IB-MECA (100 nM) caused an
inhibitory effect on cystic cell proliferation (Fig. 3B). This inhibition
was deduced to be receptor-mediated as it was reverted by addition
of the antagonist MRE3008F20. Results of dose-response analyses
with 1, 10, and 100 nM Cl-IB-MECA treatment for 24 h (Fig. 3C)
showed that 10 and 100 nM concentrations decreased cell prolifera-
tion to a greater extent in cystic than in tubular cells (0.61±0.021
and 0.49±0.13 in cystic vs. 0.75±0.08 and 0.91±0.18 in tubular
cells, at 100 and 10 nM respectively, pb0.05, cystic vs. tubular cells);
the 1 nM concentration did not affect cell proliferation. After the 72 h
treatment, the inhibitory effect of 10 and 100 nM Cl-IB-MECA was(A) Basal, RO 201712 (0.5 mM) and forskolin (1 μM) associated levels of cAMP in 4/5
al A2AR ligands: the non-selective agonists NECA (100 nM), the A2AAR antagonist SCH
: the agonist CHA (100 nM), the antagonist DPCPX (1 μM); (D) by typical A3AR ligands:
d 9.12 vs. 4/5 Cl-IB-MECA-treated cells. Experiments were performed as described in
Fig. 3. The inhibitory effect of Cl-IB-MECA on cell proliferation. Trypan blue-negative cells were counted after 24 and 72 h culture in 1% FBS, in the absence or presence of the agonist
Cl-IB-MECA alone or in combinationwith the antagonist MRE3008F20. (A) After 24 and 72 h of culture in 1% FBS, cell proliferationwas increased in PKD1-mutated 9.7 and 9.12 cystic
cells, as compared to 4/5 tubular cells. Bars showmean±SD of at least three independent experiments in triplicate; ⁎ and ⁎⁎, pb0.05 and 0.01 vs. tubular cells. (B) Inhibitory effect of
Cl-IB-MECA (100 nM) on proliferation of 9.7 and 9.12 cells after 24 h treatment. Bars represent mean±SD of three triplicate experiments. ○ and ○○, pb0.05 and 0.01 of cystic vs.
tubular untreated cells; ⁎ and ⁎⁎, pb0.05 and 0.01 vs. Cl-IB-MECA-untreated cystic cells. The A3AR antagonist MRE3008F20 (1 μM) blunted the Cl-IB-MECA-induced inhibitory effect.
Relative decrease in cell proliferation induced by treatment with increasing concentrations of Cl-IB-MECA for 24 h (C) and 72 h (D) in 4/5 and 9.12 cells. (E) Relative decrease in cell
proliferation induced by 72 h treatment with 100 nM Cl-IB-MECA in HEK293pSsiPKD1 (clones a and b) and control HEK293pSuper cells. Bars (means±SD) express the ratios between
cell number in treated vs. untreated cells in four triplicate experiments (⁎ and ⁎⁎, pb0.05 and 0.01 in cystic vs. tubular Cl-IB-MECA-treated cells and in HEK293pSsiPKD1 vs.
HEK293pSuper Cl-IB-MECA-treated cells). (F) Changes in cell cycle phases (G0/G1, S and G2/M) of tubular and cystic cells by Cl-IB-MECA treatment. After 24 h culture in the presence
of 1% FBS and 100 nM Cl-IB-MECA alone or in combination with MRE3008F20, cells were incubated with propidium iodide and analysed as described in the Materials and methods
section. The % of cells in G0/G1, S and G2/M phases in treated cells were related to those of untreated cells. Bars show mean±SD of ratios obtained in three duplicate experiments
(one with 4/5 and 9.7 cells, two with 4/5 and 9.12 cells); ⁎, pb0.05 in combined 9.7 and 9.12 cystic vs. 4/5 tubular cells. (G) Caspase 3 activity in 4/5, 9.7 and 9.12 cells cultured for
24 h with 1% FBS and 100 nM Cl-IB-MECA, relative to untreated 4/5 cells. Bars show the mean±SD of three independent experiments in duplicate.
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prevalent inhibition at 100 nM concentration (0.64±0.03 in cystic vs.
0.88±0.05 in tubular, pb0.01, Fig. 4D). This concentration was also
inhibitory in HEK293pSsiPKD1 cells (Fig. 3E), and therefore 100 nM Cl-
IB-MECA was used in the subsequent experiments.
Analysis of cell cycle phases showed that the Cl-IB-MECA-
mediated reduction in cystic cell proliferation was associated with a
small decrease in the S phase and an increase in the G2/M phase,
effects which were blunted by the addition of MRE3008F20 (Fig. 3F).As the increase in the G2/M phase may have been dependent on
increased apoptosis, analysis of caspase 3 activity was performed.
Basal activity was not modiﬁed by Cl-IB-MECA (Fig. 3G).
3.4. A3AR activation decreases Erk and S6 kinase phosphorylation in PC1-
deﬁcient cells
As cAMP was found to activate ERK and increase ADPKD epithelial
cell proliferation [18], we decided to investigate whether the
Fig. 4. Inhibitory effect of 100 nM Cl-IB-MECA on activation of ERK1/2 and P70 S6K in PC1-deﬁcient cells. Levels of phosphorylated ERK1/2 in 4/5 and 9.12 cells (A) and in
HEK293pSuper and HEK293pSsiPKD1 cells (B); levels of phosphorylated P70S6K in 4/5 and 9.12 cells (C); p21WAF1 levels are also shown (D). PC1 expression levels shown in the inset of
part (B) were obtained as described in the legend of Fig. 1A. Phosphorylated and non-phosphorylated proteins (20 μg/lane), were detected in total lysates of cells, cultured for 24 h
with 1% FBS, 100 nM Cl-IB-MECA in absence or presence of 1 μMMRE3008F20, as described in theMaterials and methods section. Levels of phosphorylated proteins were normalized
for those of non-phosphorylated ones, and those of p21WAF1 were normalized for the content of β-actin. The ﬁndings obtained were related to those of untreated control cells and
represented as mean±SD of three independent experiments. ⁎ and ⁎⁎ indicate statistical signiﬁcance from 4/5 and HEK293pSuper untreated cells (pb0.05 and 0.01). ○, indicates
statistical signiﬁcance from 9.12 and HEK293pSsiPKD1a untreated vs. Cl-IB-MECA-treated cells (pb0.05). ○○, indicates statistical signiﬁcance from HEK293pSsiPKD1b untreated vs. Cl-IB-
MECA-treated cells (pb0.01).
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with reduced ERK1/2 activation in tubular and cystic cells. As
expected from the increased proliferation, levels of phosphorylated
ERK1/2 (p-ERK) were 1.36-fold higher in cystic than in tubular cells
(pb0.05) (Fig. 4A). Addition of 100 nM Cl-IB-MECA reduced p-ERK
levels in cystic but not in tubular cells, and this effect was deduced tobe A3AR receptor-speciﬁc as it was reverted by MRE 3008F20.
Reduction in phosphorylated ERK1/2 by Cl-IB-MECA was conﬁrmed
in PC1-depleted HEK293pSsiPKD1 cells (Fig. 4B).
It has recently been shown that ERK phosphorylates the tumor
suppressor TSC2, leading to the disruption of the TSC1–TSC2
complex and ultimately unleashing mTOR kinase activity [30], an
538 G. Aguiari et al. / Biochimica et Biophysica Acta 1792 (2009) 531–540important signalling pathway which leads to cystogenesis [31]. In
fact, cystic epithelial cells in ADPKD patients exhibit elevated levels
of phosphorylated S6 kinase (S6K), the main substrate for mTOR
kinase [31]. Therefore the effect of A3AR activation was also
investigated in S6K p70. As expected, the phosphorylated S6K levels
were higher in cystic than in tubular cells, and were reduced by Cl-
IB-MECA (Fig. 4C).Fig. 5. NFkB activation and A3AR expression in kidney cell lines. NFkB-GFP nuclear translo
HEK293pSsiPKD1b cells (D). Cells were grown in 1% FBS on coverslips and, after 24 h transfectio
described in theMaterials andmethods section. The percentage of ﬂuorescent cells in the cyto
are shown. ⁎⁎, pb0.01 of 9.7 and 9.12 vs. 4/5 cells in 3 duplicate experiments (B). Increase in l
cells, was related to control cells. ⁎⁎ and ⁎⁎⁎ indicate statistical signiﬁcance from control cell
mRNA levels in cystic cells. Cells were cultured for 48 h in 1% FBS and in presence or abse
parthenolide-treated and untreated 4/5, 9.7 and 9.12 cells. The levels of A3AR mRNA wer
Materials and methods. ⁎⁎ indicates statistical signiﬁcance from untreated cells (pb0.01)The expression of p21WAF1, which plays a central role in the
regulation of the cell cycle, is induced by PKD1 [7], and could be
implicated in the ERK signal strength [32], was also investigated by
immunoblotting (Fig. 4D); the positivity of p21 bands increased in
cystic Cl-IB-MECA-treated cells.
Together, these results support a modulatory role of A3AR on cystic
cell proliferation.cation is shown in tubular and cystic cells (A), and in HEK293pS, HEK293pSsiPKD1a and
nwith the NFkB-GFP construct in 1% FBS, were analysed by ﬂuorescence microscope as
plasm (C) and in the nucleus (N) of 4/5 (n=153), 9.7 (n=146) and 9.12 (n=130) cells
uciferase promoter activity in NFkB-pTA-luc-transfected 9.12 (C) and HEK293pSsiPKD1(E)
s (pb0.01 and 0.001). (F) Parthenolide, an inhibitor of NFkB activation,29 reduced A3AR
nce of 50 nM parthenolide. A3AR mRNA was related to the content of actin mRNA in
e measured by real-time RT-PCR and related to those of actin mRNA as described in
.
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Activation of A3AR promoter was found to be associated with
activation of the transcription factor NFkB in peripheral blood mono-
nuclear cells of arthritis patients [33], and NFkB activity is known to be
related to increased cell survival. We therefore investigated the
possible association between NFkB and A3AR levels in cystic cells.
These cells showed abnormally increased NFkB activity. In particular,
the nuclear ﬂuorescence of transiently transfected NFkB-GFP (Fig. 5A
and B), as well as the NFkB-dependent promoter activity (Fig. 5C), was
higher in cystic than in tubular cells. A link between NFkB activation
and increasedA3ARgeneexpression could thereforeexist in cystic cells.
As similar resultswere found inPC1-depletedHEK293pSsiPKD1 cells (Fig.
5D and E), NFkB activation may be imputed to PC1 impairment. This
hypothesis is supported by the ﬁnding that inhibition of NFkB activity
by pre-treatment with parthenolide (inhibitor of the IK kinase) [34]
results in reduction of A3ARmRNA levels (Fig. 5F). The increase inA3AR
expression in cystic cells, therefore, is supported by increased NFkB
binding activity.
4. Discussion
Evidence supports the concept that the kidney expresses speciﬁc
adenosine membrane receptors, that adenosine plays a vital role in
the metabolic control of kidney function, and that interstitial
adenosine can derive from extracellular breakdown of AMP, cAMP
and ATP [19]. Since receptor levels are rate limiting for the actions
of adenosine [19], receptor expression is of particular importance in
physiological and pathological conditions such as polycystic kidney
disease, especially considering that ATP concentration is elevated in
cyst luminal ﬂuid [35].
Here we demonstrate that loss of PC1 in PKD1-mutated cystic cells
and in PC1-depleted HEK 293 cells, leads to a speciﬁc increase in the
expression of the A3 adenosine receptor subtype, a G-protein-coupled
receptor which inhibits AC activity [16]. We therefore focused on
changes in cAMP levels and cAMP-dependent processes in tubular and
cystic cells. Consistently with increased A3AR levels, the activation of
A3AR in cystic cells with the selective agonist Cl-IB-MECA resulted in a
signiﬁcant decrease in RO201712 and forskolin-associated cAMP
levels, as compared to tubular cells. In contrast, activation of A1, A2A
and A2B receptors, which are similarly co-expressed in these cells, did
not yield differences in cAMP levels between cystic and tubular cells.
In light of the proliferative response to cAMP of cyst-derived cells
[10–14], this alteration represents an interesting characteristic of
cystic cells because, as discussed herein, it may lead theway to a novel
therapeutic approach for ADPKD. Approaches to reduce kidney cAMP
levels in ADPKD have been indeed already taken [2], and the therapy
with octreotide, a somatostatin analogue activating Gi-coupled
receptors, has been indeed found to be effective in slowing renal
volume expansion [36].
In particular, the activation of A3AR by Cl-IB-MECA is associated
with a reduction in cell proliferation, which is prevalent in cystic cells,
with a maximal ∼35% inhibition. As this inhibitory effect is exerted by
nanomolar concentrations (10 and 100 nM) of the agonist and blunted
by the selective A3AR antagonist MRE3008F20, it was shown to be a
receptor-mediated effect and associated with the decrease in cAMP.
Moreover, the agonist selectivity at this concentration may exclude
involvement of A1AR, which is expressed at high level in both cystic
and tubular cells. The loss of inhibitory effect observed at higher doses
of Cl-IB-MECA (1000 nM) could be attributed to interactionwith other
AR subtypes, or to agonist-dependent desensitization–degradation
and down-regulation of A3AR that has been demonstrated by other
authors in various cell systems [37].
Earlier studies have demonstrated that micromolar concentrations
of A3AR agonists such as Cl-IB-MECA induce apoptosis in different cell
types [17,38]. In our study, the Cl-IB-MECA-induced reduction inproliferation was not found to be associated with increased cell death
by necrosis or apoptosis, since neither the number of trypan blue
positive cells (data not shown) nor the activity of caspase 3 were
modiﬁed by the 100 nM treatment. Instead, cell cycle studies showed
that Cl-IB-MECA impairs cell cycle progression by increasing the G2/
M phase in cystic cells. This ﬁnding is consistent with the reduction in
proliferation provoked by A3AR activation in A3AR-transfected CHO
cells, which was due to an augmented G2/M phase [39].
The reduction in cystic cell proliferation by Cl-IB-MECA occurs via
modulation of the ERK1/2 pathway by A3AR-mediated reduction in
phosphorylated-ERK levels. This ﬁnding is consistent with the stimu-
latory effect exerted by cAMP on MAPK/ERK signalling in cystic cells
[10,12–14], and is also in line with the observed cell cycle changes.
Reduction in ERK activity has, in fact, been implicated in retarding the
progression frommetaphase to anaphase [32,40]. However, we cannot
exclude the hypothesis that ERK1/2 inactivation by Cl-IB-MECA via
A3AR may be partly cAMP-independent. For instance, the anti-
proliferative effect of Cl-IB-MECA and ERK1/2 inactivation in mela-
noma cells occur, in part, via a PLC/PI3K/AKT pathway [41].
An other important pathway contributing to cystic expansion and
epithelial cystic cell proliferation is the mTOR signalling; enhanced
levels of phospho-mTOR and the downstream effector phospho-S6
ribosomal protein have been indeed observed in cystic cells [31]. Cl-
IB-MECA-induced reduction in phosphorylated S6 kinase levels in
cystic cells, therefore, provides evidence for anti-proliferative and
anti-growth effects of the A3AR activation in these cells. It is
noteworthy that ERK mediates phosphorylation of TSC2/tuberin,
leading to dissociation and inactivation of the TSC1/TSC2 complex and
activation of mTOR [30]. Therefore, S6 kinase inactivation may result
from ERK inactivation. In addition, the PI3K/AKT pathway is known to
activate the mTOR pathway. Consequently, S6 kinase inactivation by
Cl-IB-MECA may exclude the involvement of AKT in the above-
mentioned ERK inactivation.
The observation that the increase in A3AR density is consistentwith
that in A3AR protein and mRNA levels strongly indicates that loss of
PKD1 gene expression leads to increased expression of the A3AR gene.
PC1 depletionmaycause an increase inA3ARgene expressionvia cAMP
elevation in cystic cells, which might upregulate the A3AR promoter
activity. Enhancement of A3AR promoter in response to elevation in
cAMP has been already demonstrated in rat vascular smooth muscle
cells and in the rat mast cell line RBL-2H3 [42]. These results suggest
the presence of a generalized mechanism in A3AR-expressing cells, by
which cAMP might control its own level via regulation of genes
involved in themodulation of AC activity [42]. However, it has recently
been shown that upregulation of A3AR in peripheral blood mono-
nuclear cells of rheumatoid arthritis patients is directly correlated to an
increase in expression of NFkB [33], and there are two NFkB/NFkB1-
binding sites in the A3AR gene promoter [33]. The hypothesis of an
associationbetweenNFkB activation andA3ARexpression is supported
by our results. Marked NFkB nuclear localization and elevated
luciferase promoter activity have, in fact, been demonstrated in cystic
cells and in two HEK293pSsiPKD1 clones, both characterized by
increased A3ARexpression. A potential role of NFkB in A3ARexpression
is further supported by the ﬁnding that NFkB inhibition by partheno-
lide reduces A3AR mRNA levels in cystic cells. In addition, these
ﬁndings strongly indicate that NFkB is activated in PKD1-defective
cells, probably contributing to cystic cell proliferation and survival.
In conclusion, our study shows that cystic cells “in vitro” and ADPKD
kidneys express increased A3AR levels, and upon A3AR activation, the
modulation of cAMP and of key signalling proteins leads to inhibition of
the growth of cystic cells. The capacity of synthetic A3AR agonists to
inhibit the growth of various tumor cell types, such asmelanoma, colon
carcinoma and lymphoma [43–46], as well as renal injury [47], renders
them as potentially useful in the treatment of ADPKD. This is certainly
an important issue, worthy of more detailed investigation in the future
with animal models of the disease.
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